Netupitant
Akynzeo (netupitant) is a small molecule pharmaceutical. Netupitant was first approved as Akynzeo on 2014-10-10. It has been approved in Europe to treat nausea, neoplasms, and vomiting. It is known to target substance-P receptor. Akynzeo's patents are valid until 2035-09-25 (FDA).
| Trade Name | Akynzeo |
|---|---|
| Common Name | Netupitant |
| Indication | nausea, neoplasms, vomiting |
| Drug Class | Tachykinin (neurokinin) receptor antagonists: NK1 receptor antagonists |
